Semaglutide (Wegovy and Ozempic): Weekly GLP-1 injection Semaglutide is an FDA-approved GLP-1 receptor agonist that mimics the activity of the natural hormone GLP-1, which regulates hunger and appetite
However, the effects of larger doses are not known
during a mixed meal challenge) or via exogenous insulin infusion (e.g
VitaStir positions itself as a physician-supervised program
Although current therapies benefit some individuals, relapse rates remain high, with most studies reporting rates exceeding 70% within one year, underscoring the necessity for more effective interventions [10, 11]
Conclusion This study demonstrated changes in the actual number of semaglutide and dulaglutide prescriptions supplied for T2D treatment between January and September 2022, with reductions in the number of semaglutide and dulaglutide prescriptions supplied coinciding with the TGA announcements of shortages for semaglutide and dulaglutide in April and June 2022, respectively